Skip to main content

Researchers Identify 53 Existing Drugs That May Block Ebola Virus From Entering Human Cells!!!

Researchers found 53 existing drugs that may keep the Ebola virus from entering human cells, a key step in the process of infection, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the National Institutes of Health (NIH), and published today in the Nature Press journal Emerging Microbes and Infections.

Among the better known drug types shown to hinder infection by an Ebola virus model: several cancer drugs, antihistamines and antibiotics. Among the most effective at keeping the virus out of human cells were microtubule inhibitors used to treat cancer.

"In light of the historic and devastating outbreak of Ebola virus disease, there is an urgent need to rapidly develop useful treatments against Ebola infection, and our study results argue that repurposing existing drugs may be among the fastest ways to achieve this," said lead author Adolfo García-Sastre, PhD, Director of the Global Health and Emerging Pathogens Institute within the Icahn School of Medicine at Mount Sinai.

"Many of the compounds identified in this study promise to become lead compounds in near-future drug development efforts studies targeting this virus," said Dr. García-Sastre, also the Fishberg Chair and Professor of Medicine (Infectious Diseases) within the School.

There is no approved treatment for Ebola virus infection, and the estimated mortality rate of the current Ebola outbreak is nearly 70 percent in many areas. Antibody based therapy (e.g. ZMapp) has proven effective in animal studies, and has been used for the treatment of a few patients, but has not been confirmed in clinical trials. It is also expensive to make and in short supply. Ebola vaccine trials are getting underway as well, but vaccines will not be available for some time.

"NCATS is all about getting more treatments to more patients more quickly, and this is never more urgent than in the case of a public health emergency like Ebola," said Christopher P. Austin, MD, Director of the National Center for Advancing Translational Sciences (NCATS), part of the NIH, which also led the study.

"This remarkable team of scientists combined NCATS' expertise in drug screening and development with Mt. Sinai's expertise in Ebola virology to rapidly identified candidate treatments for Ebola infection."

Specifically, the research team used a miniaturized, high-speed technology to screen through sample libraries of 2,816 compounds already approved by the US Food and Drug Administration for other uses. Their assay was designed to identify compounds that blocked the ability of the Ebola virus to enter and infect human cells by at least 50 percent.

While fully intact Ebola virus is a biosafety level (BSL) 4 pathogen and dangerous to work with, the team created a virus-like particle comprised of the Ebola proteins (glycoproteins and matrix proteins) that enable the virus to enter cells, but without many of the genes and proteins that make the virus deadly. When they inserted a fluorescent reporter protein in this virus-like shell, their test became capable of high-speed screening to see which drugs blocked the entry of Ebola-like viral particles into cells as measured by fluorescence. These Ebola mimics can be studied in a BSL-2 facility, making them much safer to work with.

The team's screen yielded 53 drugs that block Ebola virus-like particles from entering human cells. Along with the drug types mentioned above, other categories that blocked viral entry included estrogen receptor modulators used against cancer and serotonin reuptake inhibitors used to treat depression. Some of the compounds had been shown by previous studies to counter Ebola lifecycle steps. Next steps include testing of the re-purposed drug candidates in animal studies to see if useful doses against the virus come with toxic side effects. If any of prove to be safe and effective, the "government may opt to deploy them in the outbreak areas," said Dr. García-Sastre.

Source: The Mount Sinai Hospital / Mount Sinai School of Medicine

Comments

Popular posts from this blog

Meet Africa's youngest mum

A Kenyan young girl named Gladys Chelagat, became the youngest mother in Africa as, she gave birth at age 10. Gladys gave birth to her baby weighing 2.8kg at Kericho District Hospital in Kenya, though with the aid of a cesarean section (CS) as she was too young to have a normal delivery.‎ Doctors said that it's been close to 3 years since she gave birth and the circumstances behind this story is yet  to be ascertained. The man responsible for her pregnancy is still unknown till date. ‎ The picture of the young girl holding her baby in her arms with her innocent look is still circulating on social media with a lot of controversial opinions. While some argued that its a fallacy story, others just hope and pray she and her baby gets enough support to grow and be healthy. Which ever way the story is we pray the mother and the baby are doing fine.

BREAKING: Former Super Eagles coach, Stephen Keshi is dead

The Former Super Eagles Coach, Stephen Keshi, is dead accoring to a tweet on the Nigeria Football Federation's official twitter handle @thenff ‎Emmanuel Ado a brother to the late coach says the 54-year-old died of Cardiac arrest in the early hours of Wednesday, June 8.‎ ‎ The former international football player and coach, lost his wife, Kate, last year after a prolonged battle with cancer. ‎Keshi has coached the national teams of Togo and Mali, qualifying the former to the 2006 FIFA World Cup. ‎In his last job with Nigeria, he won the 2013 Africa Cup of Nations and reached the Round of 16 at the 2014 FIFA World Cup in Brazil.‎‎‎‎

South Korea becomes first East Asian Country to Legalize Medical Marijuana

South Korea has become the first east Asian country to legalise medical cannabis in a surprising move to expand the treatment options for patients with epilepsy and other rare diseases in the conservative country. The country’s national assembly approved amending the Act on the Management of Narcotic Drugs on Friday to allow non-hallucinogenic doses of medical marijuana. Still, using weed even for medical purpose will be strictly controlled with patients required to apply to the Korea Orphan Drug Centre, a government body facilitating patient access to rare medicines, after receiving a doctor’s prescription. Approval will be granted on a case-by-case basis, according to the country’s Ministry of Food and Drug Safety. South Korea has some of the toughest rules on cannabis consumption with citizens prosecuted for using weed in other countries where recreational marijuana is legalised. Under the country’s anti-drug laws, smoking and trading marijuana remains illegal with th...